ArticleSarcoma2021
Sarcoma of the Breast: Clinical Characteristics and Outcomes of 991 Patients from the National Cancer Database.
Article in Sarcoma, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Primary breast leiomyosarcoma: prognostic factors and treatment outcomes - a systematic review and case report (1969-2023).Frontiers in oncology · 2025Pooled it
- Primary Breast Sarcoma: A Case Report at Kuwait Cancer Center and Review of the Literature.Cureus · 2026Article
- Socioeconomic Status and Survival in Sarcomas of the Breast: Nationwide Cohort Study.Annals of surgical oncology · 2026Article
- The Presence of SFRP1 Reduces the High Risk of Metastasis in RANKL-Expressing Canine Mammary Cancers.Animals : an open access journal from MDPI · 2026Article
- Article
- Malignant Mesenchymal Tumors of the Breast: Current Challenges and New Perspectives on Primary Sarcomas and Malignant Phyllodes Tumors.Life (Basel, Switzerland) · 2025Review
- Differential diagnosis of primary mesenchymal neoplasms of the breast.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Case Report: Primary breast leiomyosarcoma in an 84-year-old male.Frontiers in oncology · 2025Article
- Rare Breast Cancers Review.Healthcare (Basel, Switzerland) · 2024Review
- Clinical perspectives and outcomes of the giant breast phyllodes tumor and sarcoma: a real-world retrospective study.BMC cancer · 2023Article
- Breast Sarcomas, Phyllodes Tumors, and Desmoid Tumors: Turning the Magnifying Glass on Rare and Aggressive Entities.Cancers · 2023Review
- Primary Breast Sarcoma: A Two-Centre Analysis and Review of Literature.Breast care (Basel, Switzerland) · 2023Article
- Modern Breast Cancer Surgery 1st Central-Eastern European Professional Consensus Statement on Breast Cancer.Pathology oncology research : POR · 2022Article
- A Rare Case of Primary Chondrosarcoma of the Breast: A Case Report and Comprehensive Literature Review.Discoveries (Craiova, Romania)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSarcoma of the breast is a rare malignancy with heterogeneous histology. Angiosarcoma, including secondary angiosarcoma from previous radiation, is the most common type of sarcoma of the breast. Other types of sarcomas of the breast have limited clinical and survival information.
methodsWe obtained clinicopathological data and survival outcomes from the patients with sarcoma of the breast, excluding angiosarcoma, that were registered in the National Cancer Database (NCDB) from 2004 to 2016. The treatment patterns and prognostic factors were analyzed.
resultsA total of 991 patients had sarcoma of the breast other than angiosarcoma. The most common histology was spindle cell sarcoma (13.4%), followed by leiomyosarcoma (11.7%) and giant cell sarcoma (10.1%). Surgical resection was performed in 894 out of 991 patients (90.2%), including R0 resection achieved in 781 (87.4%). The patients who received surgery showed better survival than the patients without surgery regardless of radiation therapy. When radiation was added to the surgical management, the OS (overall survival) benefit was marginally significant (hazard ratio 1.30 (CI 1.01-1.67),
conclusionsSurgical resection seems to be the most important treatment modality in sarcoma of the breast from the analysis of a large database. Radiation therapy added a minor survival benefit to the patients who received surgical resection. Systemic chemotherapy did not play a clear role in sarcoma of the breast.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.